Synerheal Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 20-12-2024
- Paid Up Capital ₹ 0.50 M
as on 20-12-2024
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2023)
- Profit 75.80%
(FY 2023)
- Ebitda 24.50%
(FY 2023)
- Net Worth -0.63%
(FY 2023)
- Total Assets -0.45%
(FY 2023)
About Synerheal Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Naveed Ahmed, Amala Parachuru, Perumal Sathiamurthi, and One other member serve as directors at the Company.
- CIN/LLPIN
U24297TN2015PTC099937
- Company No.
099937
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Apr 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Synerheal Pharmaceuticals Private Limited offer?
Synerheal Pharmaceuticals Private Limited offers a wide range of products and services, including Health Conditions, First Aid.
Who are the key members and board of directors at Synerheal Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naveed Ahmed  | Director | 06-Apr-2015 | Current |
| Amala Parachuru | Director | 26-Apr-2024 | Current |
| Perumal Sathiamurthi | Director | 26-Apr-2024 | Current |
| Selvaraj Deepa | Director | 26-Jul-2024 | Current |
Financial Performance of Synerheal Pharmaceuticals.
Synerheal Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 75.8% increase in profit. The company's net worth dipped by a decrease of 0.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Synerheal Pharmaceuticals?
In 2023, Synerheal Pharmaceuticals had a public holding of 5.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Synerheal Pharmaceuticals?
Unlock and access historical data on people associated with Synerheal Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Synerheal Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Synerheal Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
